Do statins reduce the risk of glaucoma? review of the evidences
DOI:
https://doi.org/10.30827/ars.v62i4.21463Keywords:
statins; hmg coa inhibitors; glaucomaAbstract
Introduction: The objectives of this article are to review and summarize the updated published data that show the relation between treatment with statins and the incidence and progression of glaucoma. We also aimed to pose a hypothesis to explain the protective effects of statins and its association with glaucoma risk.
Method: a review of the literature was carried out in the PubMed database considering the MeSH terms “statins, hmg coa” or “hmg coa inhibitors” and “glaucoma” or “open angle glaucoma” or “intraocular pressure”. All articles including clinical studies and meta-analysis were selected. Comments, letters to editors, retracted articles and research on animal models were excluded. All the articles were published from 2004. 17 articles were finally selected for review.
Results: most of the studies showed a protective effect of statins on incidence or progression of open angle glaucoma. Nevertheless, other studies did not find a significant association and even one study found association between statin treatment at high doses and more incidence of glaucoma. Neuroprotective effects of statin and inhibition of Rho-kinase may help explain the described effects.
Conclusions: The published results are not enough evidence to support statin recommendation as preventive treatment for the incidence or progression of glaucoma.
Downloads
References
Schmeer C, Kretz A, Isenmann S. Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases. CNS Neurol Disord Drug Targets. 2007; 6(4): 282-287. DOI: 10.2174/187152707781387260
Stein JD, Newman-Casey PA, Talwar N, Nan B, Richards JE, Musch DC. The relationship between statin use and open-angle glaucoma. Ophthalmology. 2012; 119(10): 2074-2081. DOI: 10.1016/j.ophtha.2012.04.029
Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Ateroesclerosis y metabolismo lipoproteico. En: Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G, editores. Farmacología. 9ª ed. Barcelona: Elsevier; 2020. p.310-318.
Villarreal G Jr, Chatterjee A, Oh SS, Oh DJ, Rhee DJ. Pharmacological regulation of SPARC by lovastatin in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2014; 55(3): 1657-1665. DOI: 10.1167/iovs.13-12712
Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on cardiovascular system. Circ Res 2017;120 (1): 229-243. DOI: 10.1161/CIRCRESAHA.116.308537
Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific Inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001; 42(5):1029-1037.
Martín PY, Piloto DI, Álvarez CG, Fumero GF, Rodríguez RD, Sánchez AL. Fisiología trabecular y glaucoma de ángulo abierto. Rev Cuba Oftalmol. 2012; 25(3): 458-466.
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121:2081–2090. DOI: 10.1016/j.ophtha.2014.05.013
Olson EA, Hainsworth DP, Davis G, Hagan JC. Eye on statins: a comprehensive review. Mo Med. 2013; 110(4): 344-348.
Wierzbowska J, Robaszkiewicz J, Figurska M, Stankiewicz A. Future possibilities in glaucoma therapy. Med Sci Monit. 2010; 16(11): 252-259.
Nagaoka T, Takahashi A, Sato E et al. Effect of systemic administration of simvastatin on retinal circulation. Arch Ophthalmol. 2006;124(5):665-70. DOI: 10.1001/archopht.124.5.665
McCann P, Hogg RE, Fallis R, Azuara-Blanco A. The effect of statins on intraocular pressure and on the incidence and progression of glaucoma: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2016; 57(6): 2729-2748. DOI: 10.1167/iovs.15-18595
De Castro DK, Punjabi OS, Bostrom AG et al. Effect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopy. Clin Experiment Ophthalmol. 2007; 35: 506-513. DOI: 10.1111/j.1442-9071.2007.01529.x
Iskedjian M, Walker JH, Desjardins O et al. Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study. Curr Med Res Opin. 2009; 25(8): 1879-1888. DOI: 10.1185/03007990903035083.
Owen CG, Carey IM, Shah S, et al. Hypotensive medication, statins, and the risk of glaucoma. Invest Ophthalmol Vis Sci. 2010; 51(7): 3524-3530. DOI: 10.1167/iovs.09-4821
Khawaja AP, Chan MP, Broadway DC et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology. 2014; 121: 1501-1507. DOI: 10.1016/j.ophtha.2014.02.009
Ho H, Shi Y, Chua J, et al. Association of systemic medication use with intraocular pressure in a multiethnic asian population: The Singapore Epidemiology of Eye Diseases Study. JAMA Ophthalmol. 2017;135(3):196-202. DOI: 10.1001/jamaophthalmol.2016.5318
Pappelis K, Loiselle AR, Visser S, Jansonius NM. Association of Systemic Medication Exposure With Glaucoma Progression and Glaucoma Suspect Conversion in the Groningen Longitudinal Glaucoma Study. Invest Ophthalmol Vis Sci. 2019;60(14):4548-4555. DOI: 10.1167/iovs.19-27984
McGwin G, McNeal S, Owsley C, Girkin C, Epstein D, Lee PP. Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol. 2004; 122: 822-826. DOI: 10.1001/archopht.122.6.822
Artes PH, Chauhan BC. Longitudinal changes in the visual field and optic disc in glaucoma. Prog Retin Eye Res 2005; 24: 333–354. DOI: 10.1016/j.preteyeres.2004.10.002
Leung DY, Li FC, Kwong YY, Tham CC, Chi SC, Lam DS. Simvastatin and disease stabilization in normal tension glaucoma: a cohort study. Ophthalmology. 2010; 117: 471-476. DOI: 10.1016/j.ophtha.2009.08.016
Marcus MW, Müskens RP, Ramdas WD, et al. Cholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort study. PLoS ONE. 2012; 7(1): e29724.
Talwar N, Musch DC, Stein JD. Association of daily dosage and type of statin agent with risk of open-angle glaucoma. JAMA Ophthalmol. 2017; 135(3): 263-67. DOI: 10.1371/journal.pone.0029724
Whigham B, Oddone EZ, Woolson S, et al. The influence of oral statin medications on progression of glaucomatous visual field loss: A propensity score analysis. Ophthalmic Epidemiol. 2018;25(3):207-214. DOI: 10.1080/09286586.2017.1399427
Ooba N, Iwahashi R, Nogami A, et al. Comparison between high and low potency statins in the incidence of open-angle glaucoma: A retrospective cohort study in Japanese working-age population. PLoS One 2020;15(8):e0237617. DOI: 10.1371/journal.pone.0237617
Shon K, Sung KR. Dyslipidemia, dyslipidemia treatment, and open-angle glaucoma in the Korean national health and nutrition examination survey. J Glaucoma 2019; 28(6): 550-556. DOI: 10.1097/IJG.0000000000001237
Chen HY, Hsu SY, Chang YC, et al. Association between statin use and open-angle glaucoma in hyperlipidemia patients: a Taiwanese population-based case-control study. Medicine. 2015; 94(45): e2018. DOI: 10.1097/MD.0000000000002018
Zacco A, Togo J, Spence K, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003; 23: 11104–11111. DOI: 10.1523/JNEUROSCI.23-35-11104.2003
Bösel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005; 92(6): 1386-1398. DOI: 10.1111/j.1471-4159.2004.02980.x
Honjo M, Tanihara H, Nishijima K, et al. Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina. Arch Ophthalmol. 2002; 120:1707–1713. DOI: 10.1001/archopht.120.12.1707
Song J, Deng PF, Stinnett SS, Epstein DL, Rao PV. Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. Invest Ophthalmol Vis Sci. 2005; 46(7):2424-2432. DOI: 10.1167/iovs.04-0776
Kotikoski H, Oksala O, Vapaatalo H, Aine E. Aqueous humour flow after a single oral dose of isosorbide-5-mononitrate in healthy volunteers. Acta Ophthalmol Scand. 2003; 81(4): 355-360. DOI: 10.1034/j.1600-0420.2003.00109.x
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
